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Abstract: Selective estrogen receptor modulators (SERMs) represent a class with a growing 
number of compounds that act as either estrogen receptor agonists or antagonists in a tissue-
specific manner. This article reviews lasofoxifene, a new-generation SERM that has completed 
phase III development for the prevention and treatment of osteoporosis in postmenopausal 
women. Consistent with preclinical observations, this new SERM demonstrated improved 
skeletal efficacy over raloxifene and at an oral dose of 0.5 mg/day was effective in the preven-
tion of both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. 
At the same dosage, lasofoxifene treatment also reduced estrogen receptor-positive breast cancer 
risk and the occurrence of vaginal atrophy, but, like the other SERMs, was associated with hot 
flushes and an increased risk of venous thromboembolic events. With its increased efficacy on 
the prevention of nonvertebral fractures than current available SERMs and its positive effects 
on the vagina, this new compound may represent an alternative and cost-effective therapy for 
osteoporosis in postmenopausal women.
Keywords: SERM, lasofoxifene, postmenopausal osteoporosis, fractures, bone density, 
menopause
Introduction
Osteoporosis is a skeletal disorder characterized by compromised bone strength and 
increased risk of fracture.1,2 It is one of the most common disorders in elderly subjects 
and represents a major public health problem, affecting up to 50% postmenopausal 
women and 20% of men older than 50 years.2 Worldwide, osteoporosis is estimated to 
be present in over 200 million individuals, with 75 million of these in Europe, Japan 
and the US.2,3 Its clinical significance lies in the occurrence of fractures, involving most 
commonly the forearm, the vertebral bodies and the hip, but fractures at other sites 
may be also associated with the disease. Each year more than 1.5 million people suffer 
hip, vertebral, and wrist fractures due to osteoporosis. The occurrence of osteoporotic 
fractures leads to considerable mortality, morbidity, reduced mobility and decreased 
quality of life.4 Up to 50% of women who sustain a hip fracture need assistance for 
activities of daily living, about 20% will die within 1 year, and about the same per-
centage will require long-term care.5,6 Moreover, future risk of osteoporotic fractures 
is greatly increased in patients with one or more vertebral fractures.4 The burden of 
osteoporosis and fractures will further increase in absolute terms over the next years 
because of the aging of the population.7 Given the magnitude of the problem, the 
prevention and treatment of osteoporosis is, therefore, of major importance for health 
organizations in all countries.Clinical Interventions in Aging 2010:5 20
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Osteoporosis occurs as the result of multiple mechanisms 
that together cause loss of bone mass and strength.8 Failure 
to acquire optimal bone mass and strength during growth 
and or an unbalance in bone remodeling leading to bone 
loss throughout life may all contribute to the develop-
ment of the disease. In women, osteoporosis and fractures 
mainly occur as a consequence of estrogen deficiency 
after menopause9 and result from an imbalance between 
bone resorption by osteoclasts and bone formation by 
osteoblasts, leading to a net bone loss with each remod-
eling cycle. Additional age-related mechanisms such as 
vitamin D deficiency and secondary hyperparathyroidism 
or reduced mechanical loading may also increase bone loss 
in elderly subjects.
One of the major and easily measurable determinant of 
bone strength and osteoporotic fracture risk is bone mineral 
density (BMD), as assessed by dual energy X-ray absorptiom-
etry (DXA). According to World Health Organization criteria, 
osteoporosis is defined to exist when BMD values fall more 
than 2.5 standard deviations below the young adult reference 
mean.1 Many studies indicate that the risk of fragility fractures 
increases progressively as BMD declines.10,11 It has been 
estimated that the risk of new vertebral fractures increases by 
a factor of 2.0 or more for each standard deviation decrease in 
BMD, irrespective of the site of bone density measurement.10 
However, several other skeletal characteristics contribute to 
bone strength and interact with BMD in determining the risk 
of fracture. These include bone macroarchitecture (shape 
and geometry), bone microarchitecture (at the trabecular 
and cortical level), matrix and mineral composition, as well 
as the rate of bone turnover and the degree of mineralization 
or microdamage accumulation, affecting the structural and 
material properties of bone.2,12,13 The recognition and mea-
surement of these parameters is becoming more important, 
and their incorporation into algorithms of fracture detection 
remains the subject of active research.
Estrogen and postmenopausal 
osteoporosis
Despite the remarkable progress made during the last two 
decades, the mechanism by which estrogen affects bone 
metabolism is complex and not fully elucidated.14–16 Estro-
gen acts through the binding and activation to two different 
estrogen receptors (ER), ERα and ERβ, which have been 
identified in osteoblasts, osteoclasts, osteocytes and bone 
marrow stromal cells.14 Positive effects of estrogen in bone 
include a decrease in the production and lifespan of osteo-
clasts (the bone resorbing cells), stimulation of osteoblast 
(the bone forming cells) activity and additional effects 
on calcium homeostasis.14,15 The antiresorptive action of 
estrogen is mediated via effects on the receptor activator of 
the NF-kappaB ligand (RANKL)/RANK/osteoprotegerin 
system (the major regulator of osteoclast activity), as well 
as by reducing the production of a number of proresorptive 
cytokines, along with direct effects on osteoclasts.15,16 Bone 
formation is also affected by estrogen deficiency with a 
reduction in the life span of osteoblast, thereby aggravating 
the negative bone balance. This combination of increased 
bone resorption and decreased bone formation accelerates 
bone loss and the structural decay of the skeleton. Impor-
tantly, the decrease in estrogen levels after menopause also 
leads to death of osteocytes by apoptosis, cells that forms a 
communicating network within the bone that is able to iden-
tify sites for remodeling when the prevailing physical loads 
are sensed.12,13 This effect on osteocyte apoptosis impairs 
the ability of bone to adapt to its loading circumstances 
and leads to a further loss of bone strength independently 
of BMD.12 Moreover, there is increasing evidence that, in 
addition to direct effects on bone cells, estrogen may be 
directly influencing calcium handling in the bowel and the 
kidney.14 ERs have been found in the gut and the kidney 
and some observations suggest that estrogen may positively 
affect calcium absorption, independently from other circu-
lating calciotropic hormones.14 Thus, estrogen deficiency, 
in addition to directly increase bone resorption, may result 
in a negative calcium balance due to an impaired calcium 
absorption from the gut and to an increased renal calcium 
excretion.
Among the several therapeutic interventions in osteo-
porosis, hormone replacement therapy (HRT, estrogen plus 
progestins) or estrogen replacement therapy (ERT) have 
traditionally been seen as the gold standard method in 
postmenopausal women for many years, as well as for the 
management of menopausal symptoms. In fact, estrogen 
replacement (via HRT or ERT) returns bone turnover to 
premenopausal levels, increases BMD and, if instituted at 
the time of menopause, completely prevents postmenopausal 
bone loss and the development of fractures.9,17,18 The best 
prospective fracture data have been provided by the Women’s 
Health Initiative (WHI), showing that 0.625 mg/day of 
conjugated equine estrogen alone or in combination with 
5 mg/day methoxyprogesterone significant reduces the 
risk of fractures at all skeletal sites compared to placebo 
in osteoporotic and nonosteoporotic women.18,19 However, 
despite biologically plausible mechanisms for cardiac pro-
tection by estrogen, and observational studies indicating Clinical Interventions in Aging 2010:5 21
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that HRT or ERT confers cardiovascular benefit,20 WHI and 
other randomized, controlled trials have failed to confirm 
any potential benefit in reducing the risk of coronary artery 
disease and stroke.21,22 Indeed, early increases in cardiac 
event and stroke rate have been seen in women taking 
combination HRT, especially in those starting treatment 
when older than 70 years.23 Moreover, estrogen replacement, 
especially if long term, leads to an increased risk of breast 
cancer and, when unopposed by progestins, endometrial 
cancer.23 Thus, HRT and ERT remain an option only for 
short-term early use for menopausal symptom management, 
with treatment individualized for each woman. In contrast, 
estrogen therapy must be long term, possibly lifelong, to 
have any lasting impact on bone health. While lower doses 
of estrogen have been shown to reduce bone turnover and 
increase BMD, prospective evidence showing a reduction 
in risk for fracture with-low dose estrogen replacement is 
lacking.24 Alternative therapies for the prevention and the 
treatment of osteoporosis in postmenopausal women include 
bisphosphonates, calcitonin, vitamin D, strontium ranelate, 
parathyroid hormone, and selective estrogen receptor modu-
lators (SERMs).
SERMs in clinical use and 
postmenopausal osteoporosis
SERMs are a class of compounds that interact with intracel-
lular ERs in target organs as estrogen agonists and antago-
nists.25 They include chemically diverse molecules that lack 
the steroid structure of estrogens, but possess a tertiary struc-
ture that allows them to bind to ERα and/or ERβ. For many 
years these compounds were classified simply by estrogen 
agonists or antagonists, but several experimental and clinical 
observations have led to rethink this classification with the 
development of the concept of “selective estrogen receptor 
modulation.”26–28
Over the past decade, different compounds that possess a 
SERM profile have been intensively studied and have proven 
to be a highly versatile group for the treatment of differ-
ent conditions associated with aging, including hormone-
responsive cancer and osteoporosis. Most of the unique 
pharmacology of SERMs as well as their agonistic and antag-
onistic activity on estrogen target tissues can be explained by 
three main interactive mechanisms:29 1) differential ERα and 
ERβ expression, 2) differential ER conformation on ligand 
binding, and 3) differential expression and binding to the 
ER of coregulator proteins (coactivators or corepressors). 
Notably, several studies clearly demonstrated that binding 
by estradiol, pure antiestrogen (ie, ICI 164,384) or different 
SERMs compounds results in a unique ER conformation for 
each ligand.30–32
Currently there are two main chemical classes of SERMs 
approved for clinical use: the triphenylethylene derivatives 
tamoxifen and toremifene that are used to treat breast cancer, 
and raloxifene, a benzothiopene derivative indicated for the 
treatment and prevention of osteoporosis and in the US for the 
prevention of breast cancer.25,29,33–35 All three also have ben-
eficial effects on serum lipids, but are associated with venous 
thromboembolism and hot flushes. The effects of raloxifene 
on bone are well established. Clinical trials demonstrated that 
at a daily dose of 60 mg is effective in the prevention and 
treatment of postmenopausal osteoporosis and vertebral frac-
tures.36–38 Although tamoxifen has a positive effect on bone 
as well, the increased risk of endometrial cancer eliminates 
it as a possible therapy for postmenopausal osteoporosis. 
Moreover, results from clinical trials and observational 
studies suggest that both raloxifene and tamoxifen are less 
potent on the skeleton than estrogen,34,39–42 and their effect 
in the prevention of hip and other nonvertebral fractures 
remains uncertain. Thus, the benefits of these compounds 
in reducing the risks of fracture and invasive breast cancer 
should be weighed against the increased risks of venous 
thromboembolism, fatal stroke, and in case of tamoxifen, 
uterine cancer. Moreover, a consistent number of women 
taking available SERMs for different indications reported 
moderate or severe vasomotor or gynecologic symptoms 
(especially vaginal dryness and hot flashes) that could hinder 
compliance. Among the different SERM compounds actually 
under investigation, ospemifene, lasofoxifene, bazedoxifene, 
and arzoxifene, have shown to be effective in animal mod-
els of osteoporosis to a comparable extent to that observed 
during conventional HRT and are now in clinical phase III 
studies or have already completed the phase III development 
program.34,43,44 In this article we revise the clinical evidence 
for the use of lasofoxifene in women after menopause and to 
discuss how it will fit into the treatment of postmenopausal 
osteoporosis.
Chemistry, pharmacokinetics 
and metabolism of lasofoxifene
Lasofoxifene (Figure 1) is a naphthalene derivative, third-
generation SERM that was discovered through a synthetic 
program aimed to isolate novel molecules with a good oral 
bioavailability and higher in vivo potency.45 This compound 
is structurally distinct from the first- and second-generation 
SERMs raloxifene (a benzothiopene derivative), tamoxifen 
and toremifene (both triphenylethylene derivatives). Clinical Interventions in Aging 2010:5 22
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Lasofoxifene selectively binds to both ERα and ERβ with 
high affinity.46,47 In particular, its half-inhibition concentration 
for ERα (1.5 nM) is similar to that seen with estradiol 
(4.8 nM) and at least 10-fold higher than those reported for 
raloxifene and tamoxifen.47–49
Lasofoxifene is well absorbed orally, and circulates 
highly bound to plasma proteins.47,49 Food does not signifi-
cantly affect its bioavailability relative to the fasting state,50 
and its metabolism occurs almost exclusively in the liver, 
through both oxidative and conjugative pathways. In differ-
ent studies this SERM demonstrated linear pharmacokinetics 
over a wide dose range (from 0.01 to 100 mg), with a mean 
time until maximum concentration (Tmax) of approximately 
6 hours, and an estimated terminal elimination half-life (t1/2) 
of approximately 6 days (150 hours), that is more than 2-fold 
longer than for raloxifene (16 to 87 hours).48,49,51–53 Moreover, 
lasofoxifene has a remarkably improved oral bioavailabil-
ity with respect to raloxifene. In fact, while raloxifene and 
other benzothiopene derivatives undergo extensive first pass 
glucuronidation, due to the presence of phenolic groups, 
lasofoxifene has a nonpolar tetrahydronaphthalene structure 
that confers an increased resistance to intestinal wall gluc-
uronidation.45,49,50,54 Both lasofoxifene and its metabolites are 
recovered primarily in the feces and secondarily in urine.55 
Hence, there is little change in the pharmacokinetics of the 
drug in patients with impaired renal function. In addition, age, 
mild to moderate hepatic impairment or use of concomitant 
medications (ie, ketaconazole, digoxin or warfarin) have not 
been associated with substantial differences in lasofoxifene 
pharmacokinetics.56–59
Preclinical studies with lasofoxifene
The effects of lasofoxifene in both skeletal and extraskeletal 
tissues have been tested in different in vitro and in vivo 
experimental models.34,47,49 Initial studies in bone cells 
showed an estrogen-like activity of lasofoxifene, with a 
proapoptotic effect on osteoclast precursors.46 Different 
short-term and long-term in vivo studies in ovariecto-
myzed (OVX) rats confirmed this in vitro evidence and 
demonstrated that lasofoxifene treatment (at doses of 10 to 
1000 µg/kg/day) reduces bone turnover and is effective in 
protecting from OVX-induced bone loss without any major 
adverse finding.45,46,60,61 In a bone histomorphometry study 
lasofoxifene (at doses of 10 to 1,000 µg/kg/day) completely 
blocked the OVX-induced decrease in trabecular number and 
thickness as well as the increase in bone resorption indices 
(osteoclast number, percent osteoclast perimeter, percent 
eroded perimeter) and bone formation indices (labeling 
perimeter, BFR/BV).46 Long-term studies in the same mod-
els showed that lasofoxifene maintains its efficacy on bone 
over time without any major adverse finding.61 Moreover, 
peripheral quantitative computerized tomography analysis 
of proximal tibial metaphysis and biomechanical testing of 
the fourth lumbar vertebra clearly indicated that lasofoxi-
fene treatment maintained bone quality and preserved bone 
strength in treated animals.61 Interestingly, lasofoxifene was 
also effective in the prevention of bone loss induced by aging 
or orchidectomy (ORX) in male models of osteoporosis, 
without significant effects on the prostate,62,63 suggesting 
a potential application of this compound for the treatment 
of osteoporosis not only in postmenopausal women but 
also in elderly men. A higher dose (10 to 100 vs 0.01 to 
0.1 µg/kg/day) was required to prevent ORX-induced than 
age-related decrease in bone mass. Importantly, at these dos-
ages lasofoxifene did not significantly affect the prostate.
The preclinical studies demonstrated extraskeletal benefits of 
lasofoxifene on serum lipids45,46,60–64 as well as chemopreventive 
and therapeutic effects on breast cancer.65,66 No uterine hyper-
trophic effects were observed at doses of 1 to 1000 mcg/kg/day 
in OVX rats,45,61 and at doses of 0.1 to 100 mcg/kg/day in 
immature (3 weeks old) or aged (17 months old) intact female 
rats.46 No toxicity was reported in the preclinical literature in 
either female and male rats of different ages.47,49
Clinical evidence with lasoxoxifene 
in osteoporosis
An extensive development clinical program has been 
conducted with lasofoxifene, including 23 clinical 
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pharmacology studies and 17 phase II/III clinical trials.67 This 
development program included more than 10,000 women 
and was designed to support the use of lasofoxifene for the 
prevention or treatment of postmenopausal osteoporosis and 
for the treatment of vulvar-vaginal atrophy.
Initial, phase I/II studies demonstrated safety and 
efficacy of lasofoxifene given over a 600-fold dose range 
(from 0.017 mg/day to 10 mg/day) after an overnight 
fast.51,52,68,69 The overall results from the dose selection 
analyses suggested that the lowest lasofoxifene dose 
necessary to achieve a fully efficacious response on BMD 
and low-density lipoprotein cholesterol (LDL-C) levels 
is 0.25 mg/day.69–71 All lasofoxifene treatment regimens 
were also associated with improvements in vaginal atrophy 
measures, namely maturation index and vaginal pH, com-
pared with placebo. In a different phase II study lasofoxi-
fene increased BMD as effectively as conjugate estrogen 
(Prempro® [premarin conjugated estrogen with medroxy-
progesterone acetate]; Wyeth Pharmeceuticals, Inc.).68,72,73 
A subsequent, 2-year, phase II study was specifically 
designed to compare the skeletal effects of lasofoxifene 
(0.25 and 1.0 mg/day) to raloxifene (60 mg/day) or placebo 
in 410 postmenopausal women (average T-score –1.0).74,75 
All women also received daily calcium (1000 mg) and 
vitamin D (250 IU) supplementation. At the lumbar spine, 
both doses of lasofoxifene significantly increased BMD 
compared with raloxifene or placebo (+1.8% and +2.2% 
for 0.25 and 1.0 mg lasofoxifene respectively; −0.1% 
and −1.7% for raloxifene and placebo, respectively) 
(Figure 2). Conversely, lasofoxifene and raloxifene were 
equally effective at increasing total hip BMD (+1.9 and 
+1.3% for 0.25 and 1.0 mg lasofoxifene respectively; 
+1.5 and –0.1% for raloxifene and placebo respectively). 
Consistent with the effects on BMD, biochemical markers 
of bone turnover significantly decreased after 2 years of 
lasofoxifene treatment with respect to placebo, at a similar 
or even greater extent than with raloxifene. Moreover, at 
2 years, both doses of lasofoxifene resulted in greater reduc-
tions in LDL-C and total cholesterol levels when compared 
with raloxifene and placebo.
The key evidence with lasofoxifene for the treatment of 
osteoporosis and vaginal atrophy in postmenopausal women 
comes from 2 phase III trials: the Osteoporosis Prevention 
and Lipid Lowering (OPAL) studies, and the Postmenopausal 
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Figure 2 effects of lasofoxifene (LAS) treatment (0.25 and 1.0 mg/day) on lumbar bone mineral density (BMD) (% change at 2 years) in the phase II comparative trial vs 
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Evaluation and Risk-Reduction with Lasofoxifene (PEARL) 
study. Both trials assessed the effects of lasofoxifene on 
BMD and bone turnover markers as well as different vagi-
nal endpoints, while only PEARL evaluated the outcome 
of fractures. Results from this trial have been only released 
in abstract form. Additional information has been derived 
from two clinical documents about lasofoxifene released 
on the web [http://www.fda.gov/ohrms/dockets/ac/08/
briefing/2008-4381b1-01-FDA.pdf and http://www.fda.gov/
ohrms/dockets/ac/08/briefing/2008-4381b1-02-Pfizer.pdf].
The OPAL trial was composed by two identical 
phase III, 24-month, prospective, multicenter, randomized, 
double-blind, placebo-controlled, parallel-group, phase III 
studies, in which 1907 nonosteoporotic women aged 40 to 
75 years (3 to 20 years postmenopausal) were randomized 
to lasofoxifene 0.025, 0.25 or 0.5 mg/day, or placebo for 
2 years.76,77 All patients received calcium or vitamin D supple-
mentation. Exclusions criteria were any disease associated 
with altered bone metabolism, malignancy within the previ-
ous 5 years, ovarian or uterine pathology, spinal deformities 
that would affect lumbar densitometry, hip prosthesis, or a 
history of nontraumatic vertebral or hip fractures. Overall, 
lasofoxifene treatment significantly increased BMD and 
decreased bone turnover compared to placebo, with benefi-
cial changes observed as early as 6 months.77 A significant 
increase in lumbar and femoral BMD at 6, 12, and 24 months 
was observed with all the three lasofoxifene doses com-
pared with a decrease observed in calcium and vitamin D 
supplemented placebo group. A significant decrease in bone 
turnover markers (osteocalcin, C-terminal telopeptide of 
type 1 collagen and N-terminal propeptide of type 1 procol-
lagen) was also observed at 6 and 24 months in lasofoxifene 
treatment groups with respect to placebo. Importantly, bone 
biopsies in lasofoxifene treated subjects showed bone of 
normal quality. Moreover, neither breast density (assessed 
by mammography in 351 women) nor breast pain increased 
with lasofoxifene treatment. Changes in signs and self-
assessed symptoms of vaginal atrophy or cognitive function 
and variations in lipid levels were also periodically analyzed 
over the 24 months of the study.77 Of interest, there was a 
significant improvement in vaginal pH at 1 and 2 years for 
all doses of lasofoxifene versus placebo. The assessment of 
the degree of vaginal maturation indicated significantly lower 
percentages of parabasal cells and significantly higher pro-
portions of intermediate and superficial cells in lasofoxifene 
treated women with respect to placebo. Moreover, at all time 
points lasofoxifene treatment was associated with significant 
reductions in total and LDL cholesterol relative to placebo 
in all treatment groups. Conversely, small but significant 
increases in triglycerides were observed at all time points 
with both lasofoxifene doses with respect to placebo.
The PEARL trial was a randomized, double-blind, 
placebo-controlled, parallel assignment study specifically 
designed to determine the safety and effectiveness of 
2 doses of lasofoxifene (0.25 and 0.5 mg/day) in reducing 
the risk of new/worsening radiographic spinal fractures at 
3 years (primary endpoint) in women with osteoporosis.68 
[http://www.clinicaltrials.gov/ct]. Secondary outcomes 
included nonvertebral fractures, BMD, bone markers, 
breast cancer, cardiovascular events, and gynecological 
safety events. The study was originally designed as a 3-year 
study, but was extended by 2 additional years via a protocol 
amendment, in order to provide long-term exposure data. 
All patients received calcium or vitamin D supplementation. 
Women were also excluded if they had other metabolic bone 
disease, if they were taking medications approved for osteo-
porosis, if they have had a recent fracture (within 1 year), or 
more than 3 prevalent vertebral fractures on baseline X-ray 
and/or a BMD  −4.5 SD at the lumbar spine or the femoral 
neck. At 3 years, lasofoxifene significantly reduced bone 
turnover markers and improved BMD at the spine (3.3% for 
both doses, P  0.001) and femoral neck (2.7% for 0.25 mg 
and 3.3% for 0.5 mg, P  0.001), compared with placebo.78–80 
A significant reduction in vertebral fracture risk was 
demonstrated with both treatment arms (31% for 0.25 mg, 
P = 0.002 and 42% for 0.5 mg, P  0.001)80 (Figure 3A). 
This effect was observed as early as 1 year for both doses of 
lasofoxifene and was sustained through 5 years. A similar 
risk reduction was observed with both doses in women with 
or without prevalent fracture at baseline. Conversely, the risk 
of nonvertebral fractures at 3 years was significantly reduced 
with lasofoxifene 0.5 mg/day (22%, P = 0.02), but not with 
lasofoxifene 0.25 mg/day (Figure 3B). The antifracture effi-
cacy at nonvertebral sites of the 0.5 mg dose was observed 
as early as 1 year and was maintained through 5 years. Based 
on these results lasofoxifene 0.5 mg/day was selected as 
the relevant dosage for the treatment of postmenopausal 
osteoporosis.
The analysis of extraskeletal outcomes of PEARL study 
confirmed preclinical evidence and indicated that lasofoxi-
fene 0.25 mg and 0.5 mg also reduces the risk of ER positive 
breast cancer (by 84% and 67%, respectively). This effect 
was also evident for all breast cancers (a composite endpoint 
consisting of ER+, ER–, invasive, and ductal cancer in situ) 
with lasofoxifene 0.5 mg dose (65% and 79% risk reduction 
compared to placebo through 3 and 5 years, respectively).67,80 Clinical Interventions in Aging 2010:5 25
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Efficacy of lasofoxifene treatment on vulvar and vaginal 
atrophy endpoints (symptoms, vaginal pH and maturation 
index, percentage of parabasal cells and of superficial cells) 
was also demonstrated with both lasofoxifene doses.67
Based on the positive results of the PEARL trial and of 
the 2-year extension on safety concerns, a FDA application 
(NDA 22-242) was submitted to request approval of Fablyn® 
(lasofoxifene tartrate, 0.5 mg, film-coated oral tablets; Pfizer) 
for the treatment of osteoporosis in postmenopausal women 
at increased risk of fracture. On September 2008, an FDA 
scientific advisory panel voted 9 to 3 that there is a population 
of postmenopausal women with osteoporosis in which the 
benefits of lasofoxifene likely outweigh the risks; however, in 
a response letter FDA asked for additional information on the 
compound. On 18 December 2008 the Committee for Medicinal 
Products for Human Use (CHMP) of the European Medicine 
Agency (EMEA) adopted a positive opinion, recommending 
to grant a marketing authorization for Fablyn 0.5 mg intended 
for treatment of osteoporosis in postmenopausal women at 
increased risk of fracture.81 The CHMP, on the basis of the 
submitted quality, safety and efficacy data, considered that there 
is a favorable benefit to risk balance for this compound.
Safety and tolerability 
of lasofoxifene
In all of the clinical trials performed to date, lasofoxifene 
appeared to be well tolerated. In general, adverse events 
were mild or moderate and usually resolved within a few 
days, without requiring treatment discontinuation. Moreover, 
there were no major changes in adverse-event frequency or 
intensity with increasing dose. In the comparative phase II 
study, the adverse event profile of lasofoxifene was similar 
to that of raloxifene.74,75 In phase III studies adverse events 
reported by more than 5% of lasofoxifene treated subjects 
included hot flashes, leg cramps and increased vaginal 
moisture.67,76,77,80
Major general safety events of special interest for any 
SERM have been comprehensively addressed in phase III 
clinical trials, and particularly in the PEARL study, as sec-
ondary endpoints [http://www.fda.gov/ohrms/dockets/ac/08/
briefing/2008-4381b1-02-Pfizer.pdf].67 Overall, there were 
three safety findings of note associated with lasofoxifene 
treatment: an increased incidence of uterine diagnostic pro-
cedures, an increase in venous thromboembolic events, and 
a slight but significant increase in all-cause mortality with 
lasofoxifene 0.25 mg (but not 0.5 mg) compared with placebo 
The gynecologic adverse events that occurred more frequently 
than placebo (leading to an increase in diagnostic procedures 
during the PEARL trial) included uterine polyps and endo-
metrial hypertrophy, both considered benign findings. These 
effects have been attributed to increased vascular permeabil-
ity by lasofoxifene, which results in uterine imbibition and 
accumulation of fluid in both the glands and stroma of the 
endometrium. This is consistent with the cystic echotexture 
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and increased endometrial thickness observed on ultrasound, 
together with the benign cystic atrophy observed on biopsy. 
Vaginal bleeding was reported with low frequency, but was 
more common in lasofoxifene-treated patients compared to 
placebo. Importantly, the 5-year extensions of the clinical 
safety database from the PEARL trial did not show any 
evidence of an increased risk of endometrial cancer or hyper-
plasia associated with the use of lasofoxifene. However, dur-
ing the 5 years of study follow up, lasofoxifene was associated 
with an approximate 2-fold increased risk of venous throm-
boembolism, mainly driven by an increased risk of deep vein 
thrombosis. Pulmonary embolism occurred less frequently 
but was also significantly increased in lasofoxifene-treated 
patients compared to placebo. Conversely, lasofoxifene was 
not associated with an increased risk of stroke. The slightly 
increased percentage of all-cause mortality was observed 
with lasofoxifene 0.25 mg on both the 3-year and 5-year 
safety data. The percentage of subjects who died in the 
0.25 mg lasofoxifene group exceeded that in the 0.5 mg 
group and was significantly greater than that in the placebo-
treated subjects based on 5-year data (90 vs 65, respectively, 
P = 0.049). The excess numbers of deaths were found pri-
marily in the noncoronary vascular and cancer categories. 
The latter did not appear to be focused in any specific organ 
system. Slightly more cancer deaths occurred in the brain, 
lung, and gastrointestinal system in the lasofoxifene-treated 
subjects.
Markers of cardiovascular risk (total cholesterol, 
LDL-cholesterol, and high sensitivity C-reactive protein) 
were measured at 3 years and showed a significant reduc-
tion in lasofoxifene-treated subjects compared to placebo. 
Moreover, lasofoxifene 0.5 mg was associated with a sig-
nificant 32% reduction in major coronary events (including 
coronary death, nonfatal myocardial infarctions, coronary 
revascularization procedures, documented new ischemic 
heart disease, and hospitalizations for unstable angina) 
through 5 years.
Patient-focused perspectives 
and cost-effectiveness
Available data from randomized trials indicate that lasofoxi-
fene is a very well tolerated and versatile compound. It can 
be taken orally with or without food with few side effects. 
Adherence could be impaired in some women because of the 
occurrence of hot flushes or vaginal bleeding.
Pharmacoeconomic evaluation on the use of lasofoxifene 
in osteoporosis prevention or treatment has been not 
released. Due to favorable extraskeletal effects and based on 
current data on fracture prevention, the cost-effectiveness 
of this compound could be improved compared with other 
antiresorptive agents. In this context, it is important to dif-
ferentiate between the effect on quality of life impact caused 
by the antifracture efficacy of an intervention and any general 
quality of life effect that it may have independently of that 
antifracture efficacy. In a UK meta-analysis considering post-
menopausal women unselected for low BMD and modeled 
for additional conditions such as breast cancer and cardio-
vascular health, only raloxifene proved cost-effective for the 
prevention of vertebral fractures at 60 years of age, with a 
cost per quality adjusted life-year (QALY) of £26,000 (assum-
ing no effect on hip fractures) that was below the estimated 
threshold of £35,000 corresponding to no treatment (with the 
assumption that all women had sufficient intakes of calcium 
and vitamin D).82 Bisphosphonates such as alendronate, 
etidronate and risedronate had a cost per QALY above that 
threshold. Moreover, none of the considered interventions 
was shown to cost-effectively reduce the risk of nonvertebral 
fractures in women unselected for low BMD. These net costs 
were markedly different by age, with some treatment regimens 
becoming cost-saving at higher age ranges in patients with 
a prior fracture. Importantly, the released results from the 
phase II comparative study and the phase III trials indicate 
that lasofoxifene has an improved efficacy on bone parameters 
(ie, markers of bone resorption and BMD) with significant 
improvement in fracture prevention (particularly in nonver-
tebral fractures) over the current leading SERM, raloxifene. 
This new SERM also retains a similar positive effect in breast 
cancer prevention to raloxifene, with potentially improved 
cardiovascular benefits. Thus if lasofoxifene will be marketed 
at a similar cost to current products, its cost-effectiveness 
should be improved with respect to raloxifene.
Conclusions
During the past 10 years, much effort has been devoted to 
understanding the skeletal effects of estrogen and the devel-
oping compounds that interact with intracellular ERs in target 
organs, such as estrogen agonist and antagonists. The search 
for a SERM molecule with an ideal pharmacologic profile, 
which has estrogen-like activity on the bone and the lipid 
profile, antiestrogenic activity on the breast and neutral activ-
ity on the uterus, represented for many years the goal to be 
achieved by pharmaceutical companies. This need has been 
further emphasized by the recent negative results from WHI 
and other randomized controlled trials on HRT, particularly 
for long-term treatment regimens. However, it is now clear 
from several observations that the ideal SERM profile for one Clinical Interventions in Aging 2010:5 27
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patient may be far from the ideal profile for another. Thus, 
it is likely that different groups of SERM compounds will 
be available in the future, each with a somewhat different 
profile that may be rationally applied to various patients with 
a spectrum of needs.
While retaining some of the adverse effects of other 
available SERMs (ie, hot flushes and an increased risk of 
venous thromboembolic events) lasofoxifene shows an 
improved skeletal efficacy with a demonstrated efficacy 
in the prevention of vertebral and nonvertebral fractures. 
The latter endpoint has not been addressed by raloxifene or 
other SERMs in clinical development such as ospemifene 
or arzoxifene. Potential additive beneficial effects of treat-
ment include vaginal atrophy, breast cancer prevention and 
heart disease. Confirmation of such positive results in these 
areas would make the drug very attractive to patients at risk 
for those conditions and postmenopausal bone loss, vastly 
extending the drug’s patient potential. Some concerns on the 
overall risk/benefit profile of lasofoxifene are related to the 
slight increase in the number of deaths observed at 5 years 
in the PEARL study in subjects treated with lasofoxifene 
0.25 mg/day versus placebo. Thus, specific studies on differ-
ent outcomes (ie, the prevention of breast cancer or coronary 
events in high risk populations) and longer-term analysis in 
larger samples for clinically relevant adverse events will 
be needed to obtain a reasonable view of the future and 
cost-effectiveness of this compound in the management of 
women’s health following menopause.
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